Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.77 +1.96%

+$0.19 today

Market cap
$68.98M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.02M

Average 1.40M

ATRA Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Atara Biotherapeutics, Inc.NASDAQ: ATRA

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin narrows to -803.3%

Net margin was -803.3% in Q1 FY2026, down 842.0 pp from a year earlier. On a trailing-twelve-month basis it was -40.9%, down 33.1 pp year over year. Over 3 fiscal years it widened by 386.2 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 1 analysts of -349.1% for the fiscal year ending Dec 2026, down from 27.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-803.3%-589.8 pp QoQ
Last fiscal yearDec 2025
27.1%+93.3 pp YoY
LTMMar 2026
-40.9%-33.1 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-842.0 pp-891.3 pp-49.3 pp
1 year+93.3 pp-376.1 pp-469.4 pp
3 years+386.2 pp-8.3 pp-394.4 pp
5 years+11.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
27.1%
Year-over-year change
+93.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How ATRA compares with its peers on the latest reported figures

  • ATRA's LTM Mar 2026 net margin of -40.9% is the 3rd highest of the 10 companies compared; the peer median is -266.1%.
  • Its year-over-year change of -33.1 pp is the 6th highest of 9, against a peer median of -11.5 pp.
  • Over three fiscal years its change of +386.2 pp compares with a peer median of +29.9 pp.
ATRA Competitors Peer median
Net Margin for ATRA and competitors
Company Period LTM level YoY 3-year change
ORMPOramed Pharmaceuticals Inc.FY20253202.5% —+4599.6 pp
CSBRChampions Oncology, Inc.LTM Jan 2026-3.9% -14.9 pp+7.1 pp
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-40.9% -33.1 pp+386.2 pp
MGNXMacroGenics, Inc.LTM Mar 2026-44.8% -8.2 pp+29.9 pp
STROSutro Biopharma, Inc.LTM Mar 2026-154.2% +214.9 pp-10.6 pp
COYACoya Therapeutics, Inc.LTM Mar 2026-266.1% +198.9 pp—
OVIDOvid Therapeutics Inc.LTM Mar 2026-339.3% +4217.8 pp+3364.5 pp
STTKShattuck Labs, Inc.LTM Mar 2026-4987.4% -3454.4 pp+10754.8 pp
CLNNClene Inc.LTM Mar 2026-25009.7% -16703.7 pp-6761.3 pp
IFRXInflaRx N.V.LTM Mar 2026-146303.9% -111837.5 pp—
CNTXContext Therapeutics Inc.FY2025— ——
Peer median (excluding ATRA) -266.1%-11.5 pp+29.9 pp

Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.34M63.57M8.57M128.94M120.77M
Cost of Revenue282M269.99M8.89M21.01M21.21M
Gross Profit(261.66M)(206.42M)(313K)107.93M99.56M
Gross Margin-1286.4%-324.7%-3.7%83.7%82.4%
Research & Development282M272.53M224.79M151.48M37.45M
Selling, General & Admin78.8M68.13M50.91M39.89M26.25M
Operating Expenses78.8M74.1M275.69M191.37M63.7M
Depreciation & Amortization9.35M5.65M4.83M5.05M2.12M
EBITDA(330.75M)(222.26M)(266M)(75.75M)38.63M
EBITDA Margin-1626.1%-349.6%-3102.7%-58.7%32.0%
Operating Income(340.46M)(280.51M)(276.01M)(83.44M)35.86M
Operating Margin-1673.9%-441.2%-3219.5%-64.7%29.7%
Interest Income367K3.06M5.43M2.11M683K
Interest Expense0373K5.29M4.62M3.79M
Other Income / Expenses367K52.22M(105K)(1.98M)(3.14M)
Income Before Tax(340.1M)(228.29M)(276.11M)(85.42M)32.72M
Pre-Tax Margin-1672.1%-359.1%-3220.7%-66.2%27.1%
Income Tax Expense46K12K15K(12K)31K
Net Income(340.14M)(228.3M)(276.13M)(85.4M)32.69M
Net Margin-1672.3%-359.1%-3220.9%-66.2%27.1%
EPS (Basic)(90.78)(55.96)(65.18)(11.41)2.61
EPS (Diluted)(90.78)(55.96)(65.18)(11.41)2.57
Weighted Avg Shares3.75M4.08M4.24M7.49M12.54M
Weighted Avg Shares (Diluted)3.75M4.08M4.24M7.49M12.72M

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.